HYTONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYTONE (HYTONE).
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
| Metabolism | Primarily hepatic via CYP3A4; topical absorption minimal but systemic metabolism occurs if absorbed. |
| Excretion | Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal |
| Half-life | 30–60 minutes (terminal elimination half-life; short duration requires frequent dosing) |
| Protein binding | 75–85% (primarily albumin and corticosteroid-binding globulin) |
| Volume of Distribution | 0.3–0.6 L/kg (highly variable, distributes into tissues including synovial fluid) |
| Bioavailability | Oral: 10–20% (extensive first-pass metabolism); Topical: <5% (intact skin); Intramuscular: 100% |
| Onset of Action | Topical: minutes to hours; Intramuscular: 24–48 hours; Intra-articular: 12–24 hours; Oral: 2–4 hours |
| Duration of Action | Topical: 6–12 hours; Intramuscular: 6–12 days; Intra-articular: 1–2 weeks; Oral: 12–36 hours |
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for topical use. For systemic absorption (e.g., extensive application or occlusive dressings), use with caution in severe renal impairment (GFR <30 mL/min) due to potential fluid/electrolyte disturbances. |
| Liver impairment | No specific adjustment for Child-Pugh A or B. For Child-Pugh C, avoid prolonged use or large areas due to risk of systemic corticosteroid effects. |
| Pediatric use | Children >2 years: Apply thin layer to affected area 1-2 times daily for ≤2 weeks. Maximum 10% of body surface area. Infants <2 years: Use only under pediatric endocrinologist guidance due to increased systemic absorption risk. |
| Geriatric use | Use lowest effective dose for shortest duration. Avoid occlusive dressings. Monitor for skin atrophy, telangiectasia, and increased systemic effects due to thinner skin and renal/hepatic function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HYTONE (HYTONE).
| Breastfeeding | Topical hydrocortisone appears to be excreted in breast milk in trace amounts (M/P ratio unknown). Use on small areas, low potency, and for short duration is considered compatible. Avoid application to breast or nipple area. Monitor infant for signs of adrenal suppression if prolonged use. |
| Teratogenic Risk | Topical corticosteroids such as hydrocortisone (HYTONE) are generally considered low risk in pregnancy. However, application to large areas, prolonged use, or occlusive dressings may increase systemic absorption. In animal studies, corticosteroids have shown teratogenicity (cleft palate). First trimester: minimal risk with topical use; avoid high potency. Second/third trimesters: use lowest potency for shortest duration. Systemic exposure sufficient to cause fetal growth restriction or adrenal suppression is unlikely with typical topical dosing. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component","Untreated bacterial, fungal, viral, or parasitic skin infections","Perioral dermatitis","Rosacea","Acne vulgaris","Use in diaper dermatitis (unless directed by physician)"]
| Precautions | ["Topical corticosteroids may cause reversible HPA axis suppression","Cushing's syndrome with systemic absorption","Local irritation, atrophy, striae, and telangiectasias","Use caution in pediatric patients due to greater skin surface-to-weight ratio","May mask signs of infection","Do not use on face, groin, or axillae for prolonged periods"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for routine short-term topical use. If extensive or prolonged use, monitor maternal serum cortisol, blood glucose, and blood pressure. Fetal monitoring: consider ultrasound for growth restriction if high-dose systemic exposure suspected. |
| Fertility Effects | Topical corticosteroids do not impair fertility. Systemic corticosteroids may suppress gonadotropin release; no evidence for topical hydrocortisone at recommended doses. |